Behrad Derakhshan
Corporate Officer/Principal bij EDGEWISE THERAPEUTICS, INC.
Vermogen: 213 947 $ op 30-04-2024
Oorsprong van het eerstegraads netwerk van Behrad Derakhshan
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 42 | |
| Public Company | Biotechnology | 14 | |
Innoskel SASU
 Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies.
4
| Holding Company | Biotechnology | 4 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland.
1
| Subsidiary | Biotechnology | 1 |
Therachon AG
1
| Extinct | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Behrad Derakhshan via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Sales & Marketing Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal Compliance Officer | |
| ALLOVIR, INC. | Biotechnology | President Chairman Corporate Officer/Principal Director/Board Member Chief Tech/Sci/R&D Officer | |
| SPRINGWORKS THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Executive Officer Chief Operating Officer Chief Tech/Sci/R&D Officer | |
| MYOKARDIA, INC. | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Compliance Officer | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Doctorate Degree Graduate Degree | |
| SCHOLAR ROCK HOLDING CORPORATION | Biotechnology | Chairman Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| ARRAY TECHNOLOGIES, INC. | Pharmaceuticals: Major | General Counsel Founder Director of Finance/CFO | |
Mission Bay Capital Management, Inc.
 Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | Investment Managers | Consultant / Advisor Corporate Officer/Principal Private Equity Investor | |
| Stanford University | College/University | Doctorate Degree Corporate Officer/Principal Graduate Degree | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Director/Board Member | |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member Founder | |
| DYNE THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| Louisiana State University | College/University | Corporate Officer/Principal Doctorate Degree | |
| Harvard Medical School | College/University | Doctorate Degree Corporate Officer/Principal | |
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Biotechnology | Director/Board Member Sales & Marketing | |
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| ACADIA PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member Public Communications Contact | |
| ARVINAS, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| Yale University | College/University | Doctorate Degree Doctorate Degree | |
| PASSAGE BIO, INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
| The University of Chicago Booth School of Business | College/University | Masters Business Admin Corporate Officer/Principal | |
ElevateBio LLC
 ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Biotechnology | Founder Chief Executive Officer | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Chairman Founder | |
| ITEOS THERAPEUTICS, INC. | Biotechnology | Chairman Founder | |
LifeEDIT Therapeutics, Inc.
 LifeEDIT Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Graduate Degree | |
Gemini Therapeutics Sub, Inc.
 Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Chairman Chief Executive Officer | |
SpringWorks Therapeutics LLC
 SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | Biotechnology | Director/Board Member Chief Executive Officer | |
| Arradial, Inc. | Director/Board Member Corporate Officer/Principal | ||
| ARS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| Stanford University School of Medicine | College/University | Doctorate Degree Doctorate Degree | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree Doctorate Degree | |
| ALPINE IMMUNE SCIENCES, INC. | Biotechnology | Director of Finance/CFO Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
| Université Catholique de Louvain | College/University | Doctorate Degree Doctorate Degree | |
| The University of Chicago | College/University | Masters Business Admin Doctorate Degree | |
| BAXALTA INC | Biotechnology | Chief Executive Officer Public Communications Contact | |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member Founder | |
| Yale School of Medicine | College/University | Doctorate Degree Doctorate Degree | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 47 |
| België | 3 |
| China | 2 |
| Italië | 2 |
Sectoraal
| Health Technology | 33 |
| Consumer Services | 12 |
| Finance | 4 |
| Commercial Services | 4 |
Operationeel
| Director/Board Member | 243 |
| Corporate Officer/Principal | 171 |
| Independent Dir/Board Member | 91 |
| Undergraduate Degree | 50 |
| Chief Tech/Sci/R&D Officer | 49 |
Sterkste connecties
| Insiders | |
|---|---|
| Stephen P. Squinto | 40 |
| Peter Thompson | 39 |
| Felix Baker | 28 |
| Jon Root | 28 |
| Laura Brege | 27 |
| William Keller | 26 |
| Dave Anderson | 21 |
| Bill Lundberg | 17 |
| Julie O'Neill | 16 |
| Kevin Koch | 15 |
| R. Carruthers | 15 |
| David Hallal | 15 |
| Saqib Islam | 15 |
| Leslie Leinwand | 14 |
| Jeremy Springhorn | 14 |
- Beurs
- Insiders
- Behrad Derakhshan
- Bedrijfsconnecties
